دلالات الصدق البنائي لمقياس القلق كسمة و القلق كحالة = Construct Validity of Trait and State Anxiety Scale

2015 ◽  
Vol 4 (6) ◽  
pp. 1-10
Author(s):  
أحمد يوسف قواسمة ◽  
راتب صايل الرحيل حمادنة
2020 ◽  
Vol 6 (4) ◽  
pp. 59-64
Author(s):  
Alexandra Bobrakova

Introduction: Taking into account the influence of the psycho-emotional sphere and its disorders on the pathogenetic mechanisms of rosacea, a comparative assessment of the clinical efficacy of a standard therapy and the complex therapy using Cortexin in papulopustular rosacea patients with moderate severity and concomitant neurological pathology was performed. The therapy influence on changes in the patients’ psycho-emotional state was also studied. Materials and methods: The study involved 216 papulopustular rosacea outpatients with moderate severity with a concomitant neurological pathology, aged 20 to 60 years. The patients were divided into 2 groups: 109 people (37 men and 72 women) in the study group, and 107 people (37 men and 70 women) in the control. All the patients received a treatment according to the ”Standard of Medical Care for Patients with Rosacea” of the Ministry of Health of the Russian Federation. The study group patients additionally received Cortexin. The study was carried out using the Zung Self-Rating Anxiety Scale (SAS), the Taylor Manifest Anxiety Scale, the Spielberger State-Trait Anxiety Inventory, and the Eysenck Personality Questionnaire. Results and discussion: The patients showed an increase in somatic manifestations of anxiety, levels of trait and state anxiety, and neuroticism initially before the start of treatment. The inclusion of Cortexin in the rosacea treatment reduced the somatic manifestations of anxiety more effectively than standard therapy against the background of a more considerable decrease in proportion of patients with its moderate and high levels. The severity of trait and stateanxiety, neuroticism was also significantly lower against the background of the Cortexin use than with the standard treatment. Conclusion: The Cortexin inclusion in the rosacea pharmacotherapy against the background of a concomitant neurological pathology contributes to a more pronounced correction of psychophysiological parameters, reflecting the neuroticism levels, trait and state anxiety, and somatic manifestations of anxiety, compared to standard treatment.


2008 ◽  
Vol 107 (3) ◽  
pp. 651-664
Author(s):  
Vassilis Barkoukis ◽  
Haralambos Tsorbatzoudis ◽  
George Grouios

2020 ◽  
Author(s):  
Lindsey M. Shain ◽  
Maryland Pao ◽  
Mary V. Tipton ◽  
Sima Zadeh Bedoya ◽  
Sun J. Kang ◽  
...  

1991 ◽  
Vol 6 (3) ◽  
pp. 119-125 ◽  
Author(s):  
D Loldrup ◽  
M Langemark ◽  
HJ Hansen ◽  
M Kastrup ◽  
K Jeppesen ◽  
...  

SummaryIn patients with chronic idiopathic pain disorders we have analysed the construct validity of the Melancholia Scale as compared to the results with the scale in primary depression. The patients (n= 253) were treated in a placebo controlled trial with either clomipramine or mianserin independently of the Melancholia score. The construct validity of the Melancholia Scale was further analysed by the testing of the intensity model of depression versus anxiety using the Beck Depression Inventory, the Hamilton Anxiety Scale, the Spielberger State-Trait Anxiety Scale, and the Melancholia Scale. The construct validity in terms of scale homogeneity was analysed by Loevinger coefficients which can be considered as a latent structure evaluation. The Melancholia Scale showed acceptable homogeneity, while the Hamilton Anxiety Scale lacked sufficient homogeneity. In total, 33% of the patients had a score of 10 or more on the Melancholia Scale (corresponding to 13 or more on the Hamilton Depression Scale). The predictive validity of the Melancholia Scale was evaluated using active treatment versus placebo response after 6 weeks of therapy. It was shown that in patients with a Melancholia Scale score of 10 or more (corresponding to “less than major depression”) 72% had full recovery when treated with clomipramine, while 36% of the placebo treated patients obtained a full recovery (P≤0.05). The patients treated with mianserin obtained a full recovery in 52%. The group of patients with a Melancholia Scale score of 10 or more scored higher also on the anxiety scales indicating that the relation between depression and anxiety is a matter of severity. The depressed patients had significantly lower imipramine binding sites than the non-depressed patients.


1976 ◽  
Vol 68 (3) ◽  
pp. 330-334 ◽  
Author(s):  
F. J. King ◽  
Darlene L. Heinrich ◽  
Robert S. Stephenson ◽  
Charles D. Spielberger

1979 ◽  
Vol 9 (3) ◽  
pp. 293-299 ◽  
Author(s):  
W. G. Warren ◽  
P. N. Chopra

Data derived from an administration of the Death Anxiety Scale [1] to Australian samples is analyzed with a view to providing comparative cross-cultural observations as well as some indication of realiability and validity in the Australian context. Measures of central tendency and dispersion and sex differences were found to be comparable with other surveys of similar groups to those of the present study. The Scale does not appear to suffer from acquisence set, is internally reliable and groups that would be expected to score lower than others, do so – providing some indication of construct validity. The Scale is not “factorially-pure,” however, and at least three “sub-scales” can be identified. These sub-scales are analyzed and discussed.


1976 ◽  
Vol 38 (1) ◽  
pp. 188-190 ◽  
Author(s):  
Douglas H. Lamb

25 high- and 25 low-anxiety prone Ss were exposed to a stress situation involving public speaking. General and situation-specific measures of trait and state anxiety were obtained. Results indicated high correlations between trait and state measures when these measures were related to the specific stress of speaking.


Sign in / Sign up

Export Citation Format

Share Document